Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We previously
characterized 1-ethyl-2-benzimidazolinone (1-EBIO), as well as the
clinically useful benzoxazoles, chlorzoxazone (CZ), and zoxazolamine
(ZOX), as pharmacological activators of the intermediate-conductance
Ca2+-activated K+ channel, hIK1. The mechanism
of activation of hIK1, as well as the highly homologous
small-conductance, Ca2+-dependent K+ channel,
rSK2, was determined following heterologous expression in
Xenopus oocytes using two-electrode voltage clamp (TEVC) and excised, inside-out patch-clamp techniques. 1-EBIO, CZ, and ZOX activated both hIK1 and rSK2 in TEVC and excised inside-out patch-clamp experiments. In excised, inside-out patches, 1-EBIO and CZ induced a
concentration-dependent activation of hIK1, with half-maximal (K1/2) values of 84 µM and 98 µM, respectively.
Similarly, CZ activated rSK2 with a K1/2 of 87 µM. In the absence of CZ, the Ca2+-dependent activation
of hIK1 was best fit with a K1/2 of 700 nM and a
Hill coefficient (n) of 2.0. rSK2 was activated by
Ca2+ with a K1/2 of 700 nM and an
n of 2.5. Addition of CZ had no effect on either the
K1/2 or n for Ca2+-dependent
activation of either hIK1 or rSK2. Rather, CZ increased channel
activity at all Ca2+ concentrations
(Vmax). Event-duration analysis revealed hIK1 was
minimally described by two open and three closed times. Activation by
1-EBIO had no effect on o1,
o2, or
c1, whereas
c2 and
c3 were
reduced from 9.0 and 92.6 ms to 5.0 and 44.1 ms, respectively. In
conclusion, we define 1-EBIO, CZ, and ZOX as the first known activators
of hIK1 and rSK2. Openers of IK and SK channels may be therapeutically
beneficial in cystic fibrosis and vascular diseases.
hIK1 channel; rSK2 channel; chlorzoxazone; zoxazolamine; 1-ethyl-2-benzimidazolinone
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CALCIUM-DEPENDENT K+ channels have
historically been subdivided into three distinct classes based on
conductance and blocker pharmacology. These include the
large-conductance (BK) channels, which are sensitive to
block by charybdotoxin (CTX) and iberio-toxin (29), the
intermediate-conductance (IK) channels, which are inhibited by CTX and
clotrimazole (19, 21, 24), and the small-conductance (SK),
apamin-sensitive (and -insensitive) K+ channels (23). Until
recently, openers of Ca2+-dependent K+ channels
had not been described. Olesen et al. (30, 31) identified a novel class
of compounds, the benzimidazolones, as direct activators of BK
channels, with the best studied being
1-(2-hydroxy-5-trifluoromethylphenyl)-5-trifluoro-methyl-2-[3H]benzimidazolone
(NS-1619) and
5-trifluoromethyl-1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-[2H]benzimidazole-2-one
(NS-004) (27, 30, 31, 34). Based on the subsequent observation that
NS-004 directly activated the cystic fibrosis transmembrane conductance
regulator (CFTR) Cl channel (16), we determined
whether NS-004 would modulate transepithelial Cl
secretion. However, NS-004 failed to stimulate Cl
secretion across the colonic cell line, T84, despite its ability to
activate an apical membrane Cl
conductance (5). In
contrast, the structurally related benzimidazolone, 1-ethyl-2-benzimidazolinone (1-EBIO) induced a sustained
Cl
secretory response in these cells (5, 6). This
difference was due to the ability of 1-EBIO to activate both the
basolateral membrane intermediate conductance,
Ca2+-dependent K+ channel (IK), as well as the
apical membrane Cl
conductance, CFTR channel (5, 6).
This coordinate activation of both membrane conductances is required to
induce a sustained Cl
secretory response. In
contrast, NS-004 and NS-1619 failed to activate the IK channel in these
epithelial cells (5, 6). Thus 1-EBIO represents the first characterized
pharmacological opener of these IK channels.
Recently, we demonstrated that the structurally related compounds
chlorzoxazone (CZ) and zoxazolamine (ZOX) similarly stimulate transepithelial Cl secretion across colonic and
airway epithelia via an activation of both basolateral IK and apical
CFTR (35). Based on these observations, we speculated that
basolateral membrane K+ channels may represent novel
pharmacological targets in cystic fibrosis therapy. CZ has been used
clinically for over 30 years as a centrally acting skeletal muscle
relaxant with limited knowledge regarding its mechanism of action.
While 1-EBIO, CZ, and ZOX activate both IK and CFTR in epithelia, their
mechanism of action is poorly understood. Thus we determined, in
detail, the mechanism by which 1-EBIO, CZ, and ZOX activate IK and SK channels.
Recently, both Ishii et al. (19) (hIK1) and Joiner et al. (21) (hSK4) reported the cloning of a human intermediate-conductance Ca2+-dependent K+ channel. A nearly identical channel (2 amino acids different) has also been recently reported in human T-lymphocytes (22, 24). We previously demonstrated that the Ca2+-dependent K+ channel expressed in colonic and airway epithelia has biophysical and pharmacological characteristics identical to those of the recently cloned hIK1. That is, it exhibits inward rectification in symmetric K+ (4, 8) and is blocked with high affinity by CTX (Ki = 3.5 nM; Refs. 6, 8) and clotrimazole (Ki = 270 nM; Refs. 7, 8). Indeed, we have demonstrated the expression of hIK1 in both human colonic (T84) and airway serous (Calu-3) cells by Northern blot analysis (14, 15). Based on the tissue distribution of hIK1, pharmacological modulators of these channels have been proposed as potential therapeutic agents for cystic fibrosis (5, 6), immunosuppression (11), sickle cell anemia (1, 19, 37), myotonic muscular dystrophy (32), and hypertension (25). Here, we demonstrate that the previously described pharmacological openers, 1-EBIO, CZ, and ZOX, activate hIK1, as well as the highly homologous rSK2, by increasing the opening rate, and hence open probability (Po), of the channel while having no effect on the affinity of the channel for Ca2+.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Channel expression. Xenopus laevis care and handling procedures were in accordance with University of Pittsburgh guidelines. X. laevis frogs were anesthetized with 3-aminobenzoic acid ethyl ester, the ovaries were surgically removed, and oocytes were dissected in modified Barth's solution (MBS) containing (in mM) 88 NaCl, 2.4 NaHCO3, 1 KCl, 0.82 MgSO4, 0.33 Ca(NO3), 0.41 CaCl2, 10 HEPES, and penicillin-streptomycin (1%) and defolliculated by digestion in calcium-free ND96 solution containing collagenase (Life Technologies). Oocytes were incubated at 19°C in MBS. pBF plasmid containing the genes for hIK1 or rSK2 (kindly supplied by J. P. Adelman, Oregon Health Sciences University) were linearized using Pvu I restriction enzyme (Boehringer Mannheim) and 5' capped mRNAs generated using SP6 polymerase (mMESSAGE mMACHINE In Vitro Transcription Kit, Ambion). mRNAs were evaluated both spectrophotometrically and by agarose gel electrophoresis with ethidium bromide staining. Oocytes were injected with 5-50 ng of mRNA 1-7 days prior to recording.
Solutions. For two-electrode voltage clamp (TEVC) recordings, oocytes were continuously superfused with high-K+ ND96 containing (in mM) 96 KCl, 1 MgCl2, 1.8 CaCl2, and 5 HEPES (pH adjusted to 7.5 with KOH) at room temperature. During inside-out patch-clamp recording, the bath contained (in mM) 145 potassium gluconate, 5 KCl, 2 MgCl2, 1 EGTA, and 10 HEPES (pH adjusted to 7.2 with KOH). Sufficient CaCl2 was added to the bath solution to obtain the desired free [Ca2+] (program kindly supplied by D.C. Dawson, Univ. of Michigan). The pipette solution contained (in mM) 140 potassium gluconate, 5 KCl, 1 CaCl2, 1 MgCl2, and 10 HEPES (pH adjusted to 7.2 with KOH).
TEVC recording. Oocytes were mounted in a recording chamber
maintained at room temperature. Macroscopic currents were measured with
the TEVC method using a GeneClamp 500B amplifier (Axon Instruments). Data were sampled at 100 Hz using Axoscope software (Axon Instruments). Electrodes were fabricated from borosilicate glass (Kimax-51, Kimble
glass), pulled on a vertical puller (Narishige), and had resistances of
0.3-5 M when filled with 3 M KCl. All recordings were performed
at a holding voltage of
60 mV, such that activation of a
K+ current resulted in an inward current flow. CTX and
apamin were applied directly to the bath during continuous perfusion,
at the indicated concentrations, such that inhibition of current was transient in nature.
Single-channel recording. Prior to patch-clamp recording, the
vitelline membrane was carefully removed from the oocyte following cell
shrinkage with hypertonic solution containing (in mM) 200 potassium
gluconate, 20 KCl, 1 MgCl2, 1 EGTA, and 10 HEPES (pH adjusted to 7.4 with KOH). Excised, inside-out single-channel currents
were recorded using a List EPC-7 amplifier (Medical Systems) and were
recorded on videotape for later analysis as described previously (4).
Pipettes were fabricated from thin-walled borosilicate glass (World
Precision Instruments). All recordings were performed at a holding
voltage of 100 mV. The voltage is referenced to the
extracellular compartment, as is the standard method for membrane potentials. Inward currents are defined as the movement of positive charge from the extracellular compartment to the intracellular compartment and are presented as downward deflections from the baseline
in all recording configurations.
Single-channel analysis was performed on records sampled at 5 kHz after low-pass filtering at 1 kHz. The product of the number of channels and the channel open probability (NPo) of the channels was determined using Biopatch software (version 3.11; Molecular Kinetics). NPo was calculated from the mean total current (I) divided by the single-channel current amplitude (i), such that NPo = I/i. The i was determined from the amplitude histogram of the current record. For single-channel recordings, the channel open probability (Po) was calculated as I/i.
For determining mean open and closed times, an open-closed transition
was considered valid if it remained in the state for at least two
sample periods (0.4 ms). Event-duration histograms for both the open
times (o1,
o2) and fast closed times
(
c1,
c2,) were constructed by binning at
1-ms intervals from 1.0 to 30-50 ms (i.e., >5 times the time
constant). To fit
c3, data were binned at 10-ms
intervals. Event-duration histograms were fit to exponential functions
to determine the open (
o) and closed (
c)
time constants.
Chemicals. Both CZ and 6-hydroxychlorzoxazone (OH-CZ) were obtained from Research Biochemicals International. ZOX was purchased from Sigma Chemical. 1-EBIO was purchased from Aldrich. These compounds were made as 1,000-fold stock solutions in DMSO. Apamin and ionomycin were obtained from Calbiochem. CTX was obtained from Accurate Chemical and Scientific and was made as a 10 µM stock solution in standard bath solution. Ionomycin was made as a 5 mM stock solution in DMSO. The disodium salt of ATP was obtained from Boehringer Mannheim, and used at a final concentration of 1 mM in bath solution containing 2 mM MgCl2 with free Ca2+ adjusted accordingly.
Data analysis. All data are presented as means ± SE, where n indicates the number of experiments. Statistical analysis was performed using the Student's t-test. A value of P < 0.05 was considered statistically significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effects of benzoxazoles on hIK1 in TEVC experiments. We
previously characterized 1-EBIO, CZ, and ZOX as direct activators of
the basolateral membrane IK in human colonic and airway epithelia (5,
6, 35). Northern blot analysis demonstrates this IK corresponds to the
recently cloned intermediate conductance Ca2+-activated
K+ channel, hIK1 (15, 19). This channel has also been given the name hSK4 (21), hKCa4 (24), and IKCa1 (13) by other investigators.
We further defined the mechanism by which these compounds activate hIK1
following heterologous expression in Xenopus oocytes. Initial
experiments were carried out using the TEVC technique. The effects of
CZ and ZOX (300 µM) on hIK1 during TEVC are shown in Fig.
1. Initially, addition of the
Ca2+ ionophore, ionomycin (1 µM), induced a variable
increase in inward current, consistent with activation of hIK1 under
our recording conditions (see METHODS). Addition of either
CZ (Fig. 1A) or ZOX (Fig. 1B) resulted in a further
activation of hIK1. The effect of ionomycin and the benzoxazoles was
inhibited by the transient addition of CTX (50 nM) during continuous
superfusion, a known blocker of hIK1 (19, 21). In a total of 24 experiments, ionomycin increased current from 0.14 ± 0.02 to
1.69 ± 0.18 µA. In 10 of these experiments, addition of CZ
induced a further increase in current to
3.30 ± 0.31 µA
(P < 0.001), and this was reduced to
1.43 ± 0.12 µA by the addition of CTX (50 nM). In an additional 10 experiments,
ZOX further increased current to
5.19 ± 0.67 µA (P < 0.001), and this was reduced to
1.73 ± 0.41 µA by CTX. We previously demonstrated that the primary metabolite of CZ, OH-CZ,
failed to activate the IK in T84 cells (35). Similarly, as shown in
Fig. 1C, OH-CZ (300 µM) failed to activate hIK1 following addition of ionomycin. However, the subsequent addition of CZ (300 µM), in the absence of OH-CZ, activated hIK1. The transient addition
of CTX resulted in a significant inhibition of this response. In four
experiments, OH-CZ did not activate hIK1 (
2.08 ± 0.73 µA,
Fig. 1D), although the current was subsequently increased to
4.25 ± 1.12 µA by the addition of CZ (P < 0.05).
Addition of CTX reduced the current to
1.17 ± 0.25 µA. CZ
and ZOX failed to increase current in the absence of ionomycin (data
not shown), suggesting that the benzoxazoles do not substitute for
Ca2+ in activating hIK1. This is similar to what we
previously described for the activation of endogenous hIK1 by 1-EBIO
(6). No effect of either ionomycin or CZ was observed in uninjected
(n = 3) or water-injected (n = 4) oocytes (data not
shown), demonstrating that CZ does not activate channels endogenously
expressed in Xenopus oocytes.
|
Effects of benzoxazoles on hIK1 in excised membrane patches.
The above results indicate that CZ and ZOX activate hIK1. This was
directly assessed using excised inside-out patch-clamp recordings on
hIK1 heterologously expressed in Xenopus oocytes. As is shown in Fig. 2A, CZ (100 µM) induced a
rapid activation of hIK1. Similarly, removal of CZ from the bath
solution resulted in a rapid return of channel activity to control
levels (Fig. 2A). This activation was not accompanied by a
change in the single-channel current (i) as determined by
gaussian fits of the amplitude histograms (Figs. 2, B and
C). Expanded channel records corresponding to control and
CZ-stimulated conditions are shown in Fig. 2, D and E,
respectively. In six experiments, CZ increased channel activity, measured as NPo, from a control value of 0.22 ± 0.11 to 2.31 ± 0.98 with no change in i (control = 3.47 ± 0.09 pA; CZ = 3.45 ± 0.12 pA). Also, ZOX (100 µM) caused a
significant increase in NPo, from a control value
of 0.29 ± 0.15 to 1.10 ± 0.38 with no change in i (control = 3.41 ± 0.05 pA; ZOX = 3.45 ± 0.07 pA, n = 5). Similar to
our TEVC data, OH-CZ (300 µM) had no effect on hIK1
NPo (control = 0.25 ± 0.14, OH-CZ = 0.21 ± 0.12; n = 5) or i (control = 3.37 ± 0.06, OH-CZ = 3.43 ± 0.13) in excised inside-out patches, whereas the subsequent
addition of CZ (300 µM) increased NPo to 7.77 ± 2.70 (n = 5). Also, following activation of hIK1 by CZ (100 µM), addition of OH-CZ (300 µM) in the continued presence of CZ had
no effect on channel activity (data not shown), suggesting OH-CZ does
not interact with the channel. These results demonstrate the direct
activation of hIK1 by CZ and ZOX but not OH-CZ.
|
The concentration dependence of this activation was determined.
Normalized concentration-response curves for CZ and ZOX on hIK1 are
shown in Fig. 3A (bath free
Ca2+ = 400 nM). The CZ-dependent activation of hIK1 was
fitted to the Hill equation, having a half-maximal
(K1/2) concentration of 98 µM and a Hill
coefficient of 2.4. A K1/2 value for ZOX was unattainable since NPo did not saturate with 600 µM ZOX, the maximum soluble concentration.
|
Effect of CZ on the Ca2+-dependent gating of hIK1. Our results demonstrate that CZ directly activates hIK1 in excised patches. As hIK1 is a Ca2+-dependent K+ channel, we determined the effect of CZ on the Ca2+ affinity of hIK1 in excised, inside-out patches (Fig. 3B). For these experiments, we used a concentration of 100 µM as this concentration correlates well with the K1/2 obtained (Fig. 3A). Free Ca2+ was varied between 80 nM (normal resting level of Ca2+ in colonic cells; Ref. 3) and 10 µM (a saturating level of Ca2+) in the absence and presence of CZ. Importantly, both Ca2+ concentration-response curves were carried out on the same patch. The average results of eight experiments are shown in Fig. 3B. In both the absence and presence of CZ, the data were fitted to the Hill equation, with a K1/2 value of 700 nM and a Hill coefficient of 2.0. These Ca2+ affinity data are in agreement with previously reported values for hIK1 (19) and the homologous channel cloned from mouse (mIK1) expressed in Xenopus oocytes (37). These data suggest that CZ activates hIK1 by increasing Vmax without shifting the apparent affinity of the channel for Ca2+. In addition, these data demonstrate that the CZ-dependent activation of hIK1 relies upon Ca2+ being elevated above resting levels (no activation was observed with 80 nM free Ca2+), consistent with our TEVC data.
Effects of 1-EBIO on hIK1. We previously reported that the
benzimidazolone, 1-EBIO modulates Cl secretion via
the direct activation of a Ca2+-dependent K+
channel in T84 and Calu-3 cells (5, 6, 8). Therefore, we assessed the
effect of 1-EBIO on hIK1 expressed in Xenopus oocytes using
TEVC and excised inside-out patch-clamp techniques. As described above,
during TEVC recording, ionomycin (1 µM) increased current from
0.13 ± 0.03 to
2.30 ± 1.12 µA (n = 6),
consistent with activation of hIK1. Addition of 1-EBIO (500 µM)
further increased current to
9.53 ± 1.77 µA, which was
blocked by CTX (50 nM;
2.80 ± 0.93 µA). In contrast to CZ,
1-EBIO was capable of activating hIK1 during TEVC in the absence of
ionomycin, albeit at very high concentrations (
1 mM) (data not shown).
We next determined the effect of 1-EBIO on hIK1 in excised, inside-out
patches. The results of one experiment are shown in Fig.
4A. In the presence of 400 nM free
Ca2+ there is little channel activity. In agreement with
the benzoxazole data, 1-EBIO (100 µM) markedly increased channel
activity (NPo). In seven experiments, 1-EBIO
increased NPo from 0.43 ± 0.22 to 7.62 ± 4.35. Similar to our results with CZ and ZOX, 1-EBIO had no effect on
i (control = 3.41 ± 0.10 pA, 1-EBIO = 3.46 ± 0.13 pA;
n = 7). A complete concentration-response curve for 1-EBIO is
shown in Fig. 4B. The data were fitted to the Hill equation with a K1/2 of 84 µM and a Hill coefficient of
1.8, similar to our results with CZ.
|
Effect of 1-EBIO on open and closed times of hIK1. Our results demonstrate that the benzimidazolones and benzoxazoles activate hIK1 via an increase in total current flow as opposed to changes in Ca2+ affinity or cooperativity. Total current flow is equal to the number of actively gating channels (N), the open probability of the channels (Po) and their single-channel current (i). Our results demonstrate that these pharmacological openers have no effect on i, similar to what we previously described for the endogenous channel (5, 6, 35). As channels were recorded in the excised patch-clamp configuration, the most likely explanation is an effect on Po. To verify this hypothesis, we determined the effect of 1-EBIO (100 µM) on single hIK1 channels. Addition of 1-EBIO resulted in a significant increase in the Po of hIK1 from 0.18 ± 0.03 to 0.65 ± 0.02 (n = 5). A portion of one of these recordings is shown in Fig 4A. In five experiments, 1-EBIO failed to affect the mean open time of the channel (control = 6.6 ± 1.1 ms, 1-EBIO = 7.0 ± 1.2 ms). In contrast, 1-EBIO significantly reduced the mean closed time of hIK1 from 39.5 ± 11.3 to 4.9 ± 0.6 ms.
We next determined which kinetic state of hIK1 1-EBIO affected, thereby
resulting in the reduced closed time. This was evaluated by
constructing open and closed time event-duration histograms from
patches containing a single channel. The results from one recording are
shown in Fig. 5. The channel records were
minimally fit by two open (o1,
o2)1 and three
closed (
c1,
c2, and
c3)
times. As predicted by the mean open time data, 1-EBIO had no effect on
o1 or
o2 of hIK1 (Fig. 5, A and
D; control,
o1 = 1.3 ± 0.2 ms,
o2 = 7.1 ± 1.2 ms; 1-EBIO,
o1 = 1.1 ± 0.2 ms,
o2 = 7.3 ± 0.8 ms; n = 5). In addition, 1-EBIO did not affect
c1 (Fig. 5, B
and E; control = 1.6 ± 0.2 ms, 1-EBIO = 1.6 ± 0.3 ms;
n = 5). However,
c2 was significantly reduced
from 9.0 ± 1.0 to 5.0 ± 0.6 ms (n = 5, Fig. 5, B
and E). Similar to
c2, 1-EBIO caused a dramatic
decrease in
c3 from 92.6 ± 4.6 to 44.1 ± 7.5 ms
(Fig. 5, C and F). The relative amplitudes of the open
duration components for the control condition were 13% for
o1 and 87% for
o2, whereas with 1-EBIO these were 11% and 89% for
o1 and
o2,
respectively. Relative amplitudes of the closed-duration components for
the control condition were 31%, 50%, and 13% for
c1,
c2, and
c3, respectively. Following addition of 1-EBIO, the relative amplitudes for
c1,
c2, and
c3 were 66%, 31%, and 3%,
respectively. For control and experimental conditions, the sum of the
events accounted for by the individual time constants
represented 94 and 99.5% of the total events,
respectively. These values for open and closed times,
coupled with their relative amplitudes, predict open probabilities of
0.30 ± 0.09 for control conditions and 0.65 ± 0.02 in the presence
of 1-EBIO. These data accurately reflect the Po
obtained in the presence of 1-EBIO (0.65 ± 0.02); however, the
Po observed in control conditions was only 0.18 ± 0.03, suggesting a fourth long closed time which could not be resolved
during our recordings (see DISCUSSION). Based on our
amplitude analysis, this time constant, which would represent 6% of
our events, is predicted to be ~200 ms in duration. In summary, these
data demonstrate that 1-EBIO increases the open probability of hIK1 by
reducing the duration of the long closed times (
c2 and
c3) of the channel, thereby increasing the channel
opening rate.
|
Effect of ATP on the activation of hIK1 by CZ. We recently
demonstrated that hIK1, heterologously expressed in Xenopus
oocytes, is activated by ATP in excised, inside-out patches (14). This activation was reversed by alkaline phosphatase, suggesting an endogenous kinase was activating hIK1 in excised patches (14). We
determined whether, in the presence of both saturating Ca2+
(10 µM free Ca2+) and ATP (1 mM, based on previous
observations; Ref. 15), CZ could further potentiate the activity of
hIK1. The effect of CZ (300 µM) on ATP-mediated activation of hIK1 in
an inside-out patch is shown in Fig.
6A. ATP (1 mM) produced a large
activation of hIK1, which was further activated by CZ, in the continued
presence of ATP. The results of six experiments are summarized in Fig. 6B. 1 mM ATP increased NPo from a control
value of 0.57 ± 0.18 to 3.39 ± 0.82. The subsequent addition of CZ
further increased NPo to 5.70 ± 1.21. These data
indicate that CZ and ATP activate hIK1 via independent mechanisms.
|
Effects of benzoxazoles on rSK2 in TEVC experiments. Both CZ
and ZOX are utilized clinically as centrally acting muscle relaxants and are known to affect the dopaminergic neurons (12, 28, 36). The
neuronal, small-conductance, Ca2+-activated K+
channels (SK) possess 42-44% sequence homology to hIK1 (19). Thus
we speculated that the benzoxazoles may similarly activate SK channels.
The effects of CZ, ZOX, and OH-CZ on rSK2 during TEVC experiments are
shown in Fig. 7. Addition of ionomycin (1 µM) induced a variable inward current response, consistent with activation of a K+ conductance in our recording conditions
(see METHODS). The subsequent addition of either CZ (100 µM, Fig. 7A) or ZOX (100 µM, Fig. 7B) further
activated rSK2. This activation was inhibited by the transient addition
of apamin (100 nM), a selective blocker of rSK2. In 29 experiments,
ionomycin increased current from 0.27 ± 0.04 to
3.16 ± 0.62 µA (Fig. 7D). In a subset of
experiments, CZ further increased current to
5.45 ± 1.29 µA
(n = 10), which was inhibited by apamin (
2.09 ± 0.74 µA). In an additional subset of experiments, ZOX further
increased current to
4.55 ± 0.68 µA (n = 10). The transient addition of apamin reduced this current to
1.15 ± 0.35 µA. In contrast, OH-CZ (100 µM) did not further activate rSK2 (
3.39 ± 1.04 µA, n = 4; Fig. 7, C and
D), although the current was subsequently increased to
4.20 ± 1.41 µA (n = 9) by the addition of CZ (300 µM), in the absence of OH-CZ. The further addition of apamin reduced
this current to
2.13 ± 0.88 µA. CZ and ZOX failed to
increase current in the absence of ionomycin (data not shown). These
results demonstrate that CZ and ZOX activate hIK1 as well as rSK2.
|
Effects of benzoxazoles on rSK2 in excised membrane patches.
The above results suggest that the benzoxazoles are direct activators of rSK2. This was evaluated using excised, inside-out patch-clamp recordings. The effect of ZOX on rSK2 in an inside-out patch is shown
in Fig. 8A. Under control
conditions (400 nM free Ca2+ in the bath), the activity of
rSK2 was low. Addition of ZOX (100 µM) caused a significant increase
in channel activity (NPo), which was readily
reversible. In seven patches, ZOX increased NPo
from a control value of 0.58 ± 0.21 to 2.05 ± 0.70 with
no change in single-channel amplitude (i; control = 1.80 ± 0.07, ZOX = 1.84 ± 0.07 pA). Similarly, CZ (100 µM) caused a
significant increase in NPo, from 5.19 ± 1.82 to
12.50 ± 3.09 with no change in i (control = 1.83 ± 0.06, CZ = 1.84 ± 0.05 pA; n = 7). Consistent with our TEVC
experiments, OH-CZ (300 µM) failed to activate rSK2 in excised inside-out patches (NPo: control = 1.97 ± 0.97, OH-CZ = 2.77 ± 1.21; n = 4), whereas the subsequent addition
of CZ caused an increase in NPo to 10.39 ± 4.44 (n = 4). OH-CZ also had no effect on i (control = 1.63 ± 0.14, OH-CZ = 1.66 ± 0.10 pA; n = 4). Average concentration-response curves for CZ and ZOX on rSK2 are shown in Fig.
8B (bath free Ca2+ = 400 nM). The CZ data were
fitted to the Hill equation with a K1/2 of 87 µM
and a Hill coefficient of 3.3. The K1/2 value is
similar to that obtained for the CZ-dependent activation of hIK1 (Fig.
3A); however, the Hill coefficient is greater for rSK2, indicating a greater level of cooperativity for agonist-dependent gating. Similar to our results on hIK1, a K1/2
value for ZOX on rSK2 was unattainable since NPo
did not saturate with 600 µM ZOX, the maximum soluble concentration.
These results confirm our TEVC data and demonstrate that the
benzoxazoles directly activate rSK2 in excised, inside-out patches.
|
Effects of CZ on the Ca2+-dependent gating of rSK2. Our results demonstrate that CZ activates hIK1 without affecting either the Ca2+ affinity or cooperativity of hIK1 (Fig. 3B). To determine the effect of CZ on the Ca2+-dependent gating of rSK2 in excised, inside-out patches, complete concentration-response curves for Ca2+ were generated in the absence and presence of CZ (100 µM). Importantly, both Ca2+ concentration-response curves were generated on the same patch. As shown in Fig. 8C, both in the absence and presence of CZ, the Ca2+-dependent gating of rSK2 was fitted to the Hill equation with an apparent K1/2 of 700 nM and a Hill coefficient of 2.5. Similar to our findings with hIK1, these data suggest that CZ activates rSK2 by increasing Vmax without shifting the apparent affinity of the channel for Ca2+. These data further demonstrate that the half-maximal Ca2+ affinities observed for hIK1 and rSK2 are not distinguishable, although the level of cooperativity appears to be greater for rSK2, in agreement with previous findings (18).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Pharmacological modulation of the intermediate conductance,
Ca2+-dependent K+ channels (IK) may prove
therapeutically beneficial in a wide array of diseases. Blockers of
this channel have long been proposed as a therapy in sickle cell anemia
(1). More recently, clotrimazole, an inhibitor of the IK channel in red
blood cells, has been utilized in clinical trials for sickle cell
anemia (1) and has been proposed for use in -thalassemia (2). The IK
channel of T-lymphocytes was also recently cloned and shown to be
nearly identical to hIK1 (22, 24). This channel is dramatically
upregulated following antigenic or mitogenic stimulation, suggesting
that it may play a critical role in the immune response (17, 22, 38).
This has led to the suggestion that inhibitors of IK may be important as immunosuppressives. More recently, it was suggested that openers of
IK and SK channels may be therapeutically beneficial in hypertension and peripheral vascular disease (10). Although several high-affinity blockers of IK have been described (19-21), openers of this class of channels have only recently been developed. We defined 1-EBIO as the
only known opener of the IK family of channels in airway and colonic
epithelia (5, 6). Subsequently, we demonstrated that the structurally
related compounds CZ and ZOX also activate IK channels (35). In
addition to activating IK channels, we also demonstrated that these
compounds activated CFTR (5, 35). This coordinate regulation of both IK
and CFTR resulted in a sustained Cl
secretory
response (5, 6, 35). Here, we define the mechanism by which these
compounds activate the recently cloned intermediate-conductance Ca2+-activated K+ channel, hIK1. We
have also characterized these compounds as the first known
pharmacological openers of the homologous, rSK2. Our findings suggest
that rSK2 is modulated via an identical mechanism by these compounds.
Although CZ was ranked among the top 100 most widely prescribed drugs
for many years, as a centrally acting muscle relaxant (36), its
mechanism of action has remained largely obscure. Both CZ and ZOX were
shown to decrease dopamine turnover in substantia nigra
neurons, and this appeared to be due to a decrease in
neuronal firing rate resulting in a pacemaker-like firing pattern (26). Interestingly, SK channels have been localized to the substantia nigra
by in situ hybridization (23). Thus a possible mechanism of action of
these muscle relaxants is the activation of neuronal SK channels,
resulting in a hyperpolarization of the membrane potential and hence
decreased firing rate. Supporting this hypothesis is the observation
that OH-CZ had no muscle relaxant activity (36); OH-CZ failed to
activate either hIK1 or rSK2 (Figs. 1 and 7). Importantly, the peak
plasma concentrations achieved during oral administration of CZ in
patients (100-200 µM; Refs. 12 and 36) is the
K1/2 we obtain for CZ on both hIK1 and rSK2 (80-90 µM), indicating these channels can serve as
pharmacological targets. However, our results do not allow us to rule
out the possibility that these compounds affect alternate ion channels resulting in their known biological effect.
Pharmacological modulation of hIK1 and rSK2 by benzoxazoles and benzimidazolones. Recently, the benzimidazolones NS-1619 and NS-004 were shown to activate maxi-K+ channels in a variety of tissues (30, 31, 34). This activation of BK channels by NS-004 and NS-1619 required the presence of cytoplasmic Ca2+, i.e., the benzimidazolones could not simply substitute for Ca2+ as an activator of the channel (27, 30, 31). We similarly demonstrated that the 1-EBIO- and CZ-dependent activation of endogenous IK channels required the presence of a slightly elevated Ca2+ concentration (6, 35). Here, we confirm these results for CZ on hIK1 and rSK2 heterologously expressed in Xenopus oocytes (Figs. 3 and 8). However, the interaction of benzimidazolones and benzoxazoles with Ca2+ appears to be distinct between the BK and IK channels. The benzimidazolones induce a parallel shift in the current (Po)-voltage relationship for activation of BK channels with no apparent shift in Vmax; analogous to the activation of BK by Ca2+ (27, 30, 31). However, to our knowledge, a complete characterization of the interaction among Ca2+, benzimidazolones, and Po has not been undertaken for the BK channels. We demonstrate that CZ activates both hIK1 and rSK2 via an increase in NPo with no change in the Ca2+ dependence of gating, i.e., both Ca2+ affinity and cooperativity were unchanged (Figs. 3 and 8). Thus the activation of hIK1 and rSK2 by benzimidazolones and benzoxazoles appears to be distinct from the mechanism described previously for BK channels.
Recently, others have shown that the Ca2+-binding protein,
calmodulin (CAM) exists tightly bound to the COOH-terminal tail of both
hIK1 and rSK2 in a Ca2+-independent manner and acts as a
common mechanism for Ca2+-dependent gating of these
channels (13, 39). Ca2+-CAM binding initiates a
conformational change in the -subunit of the channel proteins,
resulting in gating (39). In addition, recent evidence from comparison
of native IK channels and heterologously expressed hIK1 (hSK4) suggests
that accessory molecules such as CAM-kinase (22) or protein kinase
A (14) may be involved in channel regulation. These
findings suggest that the Ca2+-dependent activation of hIK1
and rSK2 by 1-EBIO, CZ, and ZOX may result from an indirect effect via
interaction of these compounds with CAM or other undescribed accessory
molecules rather than direct binding to the ion-conducting
-subunit
of the channel proteins.
Our results demonstrate that pharmacological openers of hIK1 function
by increasing NPo in excised, inside-out patches.
To further define the mechanism of action of these compounds, a kinetic analysis was undertaken. During control recordings (400 nM
Ca2+), our data demonstrate that hIK1 is minimally
described by two open (O1 and O2) and three
closed (C1, C2, and C3) states.
This is consistent with previous reports on hIK1 endogenously expressed in human erythrocytes (9, 33). We demonstrate that 1-EBIO has no effect
on the open time of the channel but causes a dramatic decrease in the mean closed time. This effect on the
closed time of the channel could not be attributed to an affect on the
fast closed state (C1). Rather, 1-EBIO decreased both long
closed times (c2 and
c3) of hIK1, thereby
increasing the opening rate of the channel and hence
Po. From our individual channel records, we were
able to calculate the Po predicted from the
relative number of events accounted for by our fitted time constants.
For 1-EBIO, we predicted a Po of 0.65, which
accurately reflected the observed Po of 0.65. However, for the control condition, our predicted Po of 0.30 was substantially higher than the
Po of 0.18 actually recorded. These data suggest
that an additional long-lived closed state exists which contributes to
channel gating. In fact, 6% of the closed-duration events from the
control record could not be accounted for by the three closed time
constants. To obtain the actual Po of 0.18, this
time constant,
c4, would be predicted to be ~200 ms.
Our results suggest that 1-EBIO and the benzoxazoles activate both hIK1 and rSK2 via a similar mechanism, i.e., an increase in total current flow (Po) with no effect on Ca2+-dependent gating. However, a detailed kinetic analysis has not been undertaken to determine whether CZ similarly affects the opening rate of rSK2. Recently, the Ca2+-dependent gating of both rSK2 (39) and hIK1 (13) have been shown to be due to a direct interaction of the channel with calmodulin, suggesting these two channels may be described by similar kinetic schemes. rSK2 was recently demonstrated to have six kinetic states, two open and four closed (18), consistent with our observations. In contrast to our results on hIK1, the benzimidazolones NS-004 and NS-1619 have been shown to increase the Po of BK via both an increase in the opening rate as well as a decrease in the closing rate of the channel (30, 31).
We recently demonstrated that ATP activates hIK1 in excised, inside-out patches and that both alkaline phosphatase and the protein kinase A pseudosubstrate, PKI-(5-24), could reverse this effect (14). These results suggest that hIK1 can be activated by an endogenous kinase that associates with the excised patch. These results are similar to what has recently been reported for endogenous hIK1 expressed in red blood cells (33). Indeed, this ATP-dependent activation produced identical effects on the Ca2+-dependent gating of hIK1, an increase in NPo with no change in either Ca2+ affinity or cooperativity. Thus we determined whether the effects of ATP and CZ were additive, suggesting divergent mechanisms of action, or mutually exclusive, suggesting similar mechanisms of action. In the presence of both saturating levels of Ca2+ (10 µM) and ATP (1 mM, based on previous observations; Refs. 14 and 15), the activity of hIK1 was potentiated by CZ in excised patches. These data suggest that CZ acts via a mechanism that is independent of ATP-mediated phosphorylation of the channel.
In conclusion, we have defined the mechanism of action for the pharmacological activation of the recently cloned intermediate-conductance (hIK1) and small-conductance (rSK2) Ca2+-activated K+ channels by the benzimidazolone, 1-EBIO, and the benzoxazoles, CZ and ZOX. We demonstrate these openers act by increasing channel open probability via a decrease in the mean duration of at least two long-lived closed states of hIK1 without affecting open-channel kinetics. These effects are independent of both ATP-mediated phosphorylation and the Ca2+-dependent gating (K1/2, Hill coefficient) of hIK1. Thus these compounds represent the first defined openers of the IK and SK family of channels and as such represent lead compounds upon which higher affinity agonists may be defined. It is expected that the development of compounds that activate hIK1 with greater specificity and affinity will be useful in defining these channels as potential therapeutic targets in diseases such as cystic fibrosis and hypertension.
![]() |
ACKNOWLEDGEMENTS |
---|
We gratefully acknowledge the superb secretarial skills of Michele Dobransky as well as the technical assistance of Cheng Zhang Shi in both oocyte injection and two-electrode voltage-clamp recording experiments.
![]() |
FOOTNOTES |
---|
This work was supported by Cystic Fibrosis Foundation Grant DEVOR 96P0 and National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-54941-01 (to D. C. Devor).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
1
A single exponential fit to our open time data
shown in Fig. 5 yielded time constants (o) of 6.3 and
6.9 ms for control and 1-EBIO, respectively. A statistical analysis of
the
2 values obtained by fitting the data to a single
exponential compared with the
2 values obtained using a
double exponential fit demonstrated a significantly greater goodness of
fit to a double exponential (P < 0.001).
Address for reprint requests and other correspondence: D. C. Devor, Dept. of Cell Biology and Physiology, Univ. of Pittsburgh School of Medicine, S312 BST, 3500 Terrace St., Pittsburgh, PA 15261 (E-mail: dd2+{at}pitt.edu).
Received 20 July 1999; accepted in final form 13 October 1999.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Brugnara, C.,
L. De Francheschi,
C. C. Armsby,
N. Saadane,
M. Trudel,
Y. Beuzard,
A. Rittenhouse,
N. Rifai,
O. Platt,
and
S. L. Alper.
A new therapeutic approach for sickle cell disease. Blockade of the red cell Ca2+-activated K+ channel by clotrimazole.
Ann. NY Acad. Sci.
763:
262-271,
1995[Medline].
2.
De Franceschi, L.,
P. Rouyer-Fessard,
S. L. Alper,
H. Jouault,
C. Brugnara,
and
Y. Beuzard.
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
Blood
87:
1188-1195,
1996
3.
Devor, D. C.,
Z. Ahmed,
and
M. E. Duffey.
Cholinergic stimulation produces oscillations of cytosolic Ca2+ in a secretory epithelial cell line, T84.
Am. J. Physiol. Cell Physiol.
260:
C598-C608,
1991
4.
Devor, D. C.,
and
R. A. Frizzell.
Calcium-mediated agonists activate an inwardly rectified K+ channel in colonic secretory cells.
Am. J. Physiol. Cell Physiol.
265:
C1271-C1280,
1993
5.
Devor, D. C.,
A. K. Singh,
R. J. Bridges,
and
R. A. Frizzell.
Modulation of Cl secretion by benzimidazolones. II. Coordinate regulation of apical GCl and basolateral GK.
Am. J. Physiol. Lung Cell. Mol. Physiol.
271:
L785-L795,
1996
6.
Devor, D. C.,
A. K. Singh,
R. A. Frizzell,
and
R. J. Bridges.
Modulation of Cl secretion by benzimidazolones. I. Direct activation of a Ca2+-dependent K+ channel.
Am. J. Physiol. Lung Cell. Mol. Physiol.
271:
L775-L784,
1996
7.
Devor, D. C.,
A. K. Singh,
A. C. Gerlach,
R. A. Frizzell,
and
R. J. Bridges.
Inhibition of intestinal Cl secretion by clotrimazole: direct effect on basolateral membrane K+ channels.
Am. J. Physiol. Cell Physiol.
273:
C531-C540,
1997
8.
Devor, D. C.,
A. K. Singh,
L. C. Lambert,
A. DeLuca,
R. A. Frizzell,
and
R. J. Bridges.
Bicarbonate and chloride secretion in Calu-3 human airway epithelial cells.
J. Gen. Physiol.
113:
743-760,
1999
9.
Dunn, P. M.
The action of blocking agents applied to the inner face of Ca2+-activated K+ channels from human erythrocytes.
J. Membr. Biol.
165:
133-143,
1998[ISI][Medline].
10.
Edwards, G.
Potassium channel modulation: what next?
Curr. Res. Ion Channel Modulators
3:
163-164,
1998.
11.
Ehring, G. R.,
H. H. Kerschbaum,
C. Eder,
A. L. Neben,
C. M. Fanger,
R. M. Khoury,
P. A. Negulescu,
and
M. D. Cahalan.
A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes.
J. Exp. Med.
188:
1593-1602,
1998
12.
Elenbaas, J. K.
Centrally acting oral skeletal muscle relaxants.
Am. J. Hosp. Pharm.
37:
1313-1323,
1980[ISI][Medline].
13.
Fanger, C. M.,
S. Ghanshani,
N. J. Logsdon,
H. Rauer,
K. Kalman,
J. Zhou,
K. Beckingham,
K. G. Chandy,
M. D. Cahalan,
and
J. Aiyar.
Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1.
J. Biol. Chem.
274:
5746-5754,
1999
14.
Gerlach, A. C.,
and
D. C. Devor.
Modulation of the human intermediate conductance Ca2+-activated K+ channel (hIK1) by PKA-mediated phosphorylation.
Pediatr. Pulmonol. Suppl.
17:
235,
1998.
15.
Gerlach, A. C.,
N. N. Gangopadhyay,
and
D. C. Devor.
Kinase-dependent regulation of the intermediate conductance, calcium-dependent potassium channel, hIK1.
J. Biol. Chem.
275:
585-598,
2000
16.
Gribkoff, V. K.,
G. Champigny,
P. Barbry,
S. I. Dworetzky,
N. A. Meanwell,
and
M. Lazdunski.
The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel.
J. Biol. Chem.
269:
10983-10986,
1994
17.
Grissmer, S.,
A. N. Nguyen,
and
M. D. Cahalan.
Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology.
J. Gen. Physiol.
102:
601-630,
1993[Abstract].
18.
Hirschberg, B.,
J. Maylie,
J. P. Adelman,
and
N. V. Marrion.
Gating of recombinant small-conductance Ca-activated K+ channels by calcium.
J. Gen. Physiol.
111:
565-581,
1998
19.
Ishii, T. M.,
C. Silvia,
B. Hirschberg,
C. T. Bond,
J. P. Adelman,
and
J. Maylie.
A human intermediate conductance calcium-activated potassium channel.
Proc. Natl. Acad. Sci. USA
94:
11651-11656,
1997
20.
Jensen, B. S.,
D. Strobaek,
P. Christophersen,
T. D. Jorgensen,
C. Hansen,
A. Silahtaroglu,
S. P. Olesen,
and
A. K. Ahring.
Characterization of the cloned human intermediate-conductance Ca2+-activated K+ channel.
Am. J. Physiol. Cell Physiol.
275:
C848-C856,
1998[Abstract].
21.
Joiner, W. J.,
L. Y. Wang,
M. D. Tang,
and
L. K. Kaczmarek.
hSK4, a member of a novel subfamily of calcium-activated potassium channels.
Proc. Natl. Acad. Sci. USA
94:
11013-11018,
1997
22.
Khanna, R.,
M. C. Chang,
W. J. Joiner,
L. K. Kaczmarek,
and
L. C. Schlichter.
hSK4/hIK1, a calmodulin-binding KCa channel in human T lymphocytes. Roles in proliferation and volume regulation.
J. Biol. Chem.
274:
14838-14849,
1999
23.
Kohler, M.,
B. Hirschberg,
C. T. Bond,
J. M. Kinzie,
N. V. Marrion,
J. Maylie,
and
J. P. Adelman.
Small-conductance, calcium-activated potassium channels from mammalian brain.
Science
273:
1709-1714,
1996
24.
Logsdon, N. J.,
J. Kang,
J. A. Togo,
E. P. Christian,
and
J. Aiyar.
A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T-lymphocytes.
J. Biol. Chem.
272:
32723-32726,
1997
25.
Marchenko, S. M.,
and
S. O. Sage.
Calcium-activated potassium channels in the endothelium of intact rat aorta.
J. Physiol. (Lond.)
492:
53-60,
1996[Abstract].
26.
Matthews, R. T.,
B. A. McMillen,
S. G. Speciale,
H. Jarrah,
P. A. Shore,
M. K. Sanghera,
P. D. Shepard,
and
D. C. German.
Effects of zoxazolamine and related centrally acting muscle relaxants on nigrostriatal dopaminergic neurons.
Brain Res. Bull.
12:
479-486,
1984[ISI][Medline].
27.
McKay, M. C.,
S. I. Dworetzky,
N. A. Meanwell,
S. P. Olesen,
P. H. Reinhart,
I. B. Levitan,
J. P. Adelman,
and
V. K. Gribkoff.
Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004.
J. Neurophysiol.
71:
1873-1882,
1994
28.
McMillen, B. A.,
H. L. Williams,
H. Lehmann,
and
P. D. Shepard.
On central muscle relaxants, strychnine-insensitive glycine receptors and two old drugs: zoxazolamine and HA-966.
J. Neural Transmission
89:
11-25,
1992[ISI].
29.
Miller, C.
The charybdotoxin family of K+ channel-blocking peptides.
Neuron
15:
5-10,
1995[ISI][Medline].
30.
Olesen, S. P.,
E. Munch,
P. Moldt,
and
J. Drejer.
Selective activation of Ca2+-dependent K+ channels by novel benzimidazolone.
Eur. J. Pharmacol.
251:
53-59,
1994[ISI][Medline].
31.
Olesen, S. P.,
E. Munch,
F. Watjen,
and
J. Drejer.
NS 004: an activator of Ca2+-dependent K+ channels in cerebellar granule cells.
Neuroreport
5:
1001-1004,
1994[ISI][Medline].
32.
Pellegrino, M.,
M. Pellegrini,
P. Bigini,
and
A. Scimemi.
Properties of Ca2+-activated K+ channels in erythrocytes from patients with myotonic muscular dystrophy.
Muscle Nerve
21:
1465-1472,
1998[ISI][Medline].
33.
Pellegrino, M.,
and
M. Pellgrini.
Modulation of Ca2+-activated K+ channels of human erythrocytes by endogenous cAMP-dependent protein kinase.
Pflügers Arch.
436:
749-756,
1998[ISI][Medline].
34.
Sellers, A. J.,
and
M. L. J. Ashford.
Activation of BKCa channels in acutely dissociated neurones from the rat ventromedial hypothalamus by NS 1619.
Br. J. Pharmacol.
113:
659-661,
1994[Abstract].
35.
Singh, A. K.,
D. C. Devor,
A. C. Gerlach,
M. Gondor,
J. M. Pilewski,
and
R. J. Bridges.
Stimulation of Cl secretion by chlorzoxazone.
J. Pharmacol. Exp. Ther.
292:
778-787,
2000
36.
Stewart, J. T.,
and
C. A. Janicki.
Chlorzoxazone.
Analyt. Profiles Drug Substances
16:
119-144,
1987.
37.
Vandorpe, D. H.,
B. E. Shmulker,
L. Jiang,
B. Lim,
J. Maylie,
J. P. Adelman,
L. de Franceschi,
M. D. Capellini,
C. Brugnara,
and
S. L. Alper.
cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation.
J. Biol. Chem.
273:
21542-21553,
1998
38.
Verheugen, J. A.,
F. Le Deist,
V. Devignot,
and
H. Korn.
Enhancement of calcium signaling and proliferation responses in activated human T lymphocytes. Inhibitory effects of K+ channel block by charybdotoxin depend on the T cell activation state.
Cell Calcium
21:
1-17,
1997[ISI][Medline].
39.
Xia, X. M.,
B. Fakler,
A. Rivard,
G. Wayman,
T. Johnson-Pais,
J. E. Keen,
T. Ishii,
B. Hirschberg,
C. T. Bond,
S. Lutsenko,
J. Maylie,
and
J. P. Adelman.
Mechanism of calcium gating in small-conductance calcium-activated potassium channels.
Nature
395:
503-507,
1998[ISI][Medline].